diosgenin has been researched along with Osteoporosis, Postmenopausal in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Li, H; Li, N; Wang, J; Wu, S; Xia, Y; Zhao, B; Zhao, F; Zhao, J; Zhao, S | 1 |
| Fu, X; Ju, D; Li, Y; Liu, H; Liu, M; Pan, J; Song, C; Wang, S; Xiang, L; Xiao, GG; Zhang, Z | 1 |
| Han, X; Peng, J; Qi, Y; Sun, H; Tao, X; Wang, C; Xu, L; Xu, Y; Yin, L | 1 |
3 other study(ies) available for diosgenin and Osteoporosis, Postmenopausal
| Article | Year |
|---|---|
Dioscin improves postmenopausal osteoporosis through inducing bone formation and inhibiting apoptosis in ovariectomized rats.
Topics: 3T3 Cells; Animals; Apoptosis; Bone Density; Bone Development; Cell Differentiation; Diosgenin; Female; Humans; Mice; Osteoporosis, Postmenopausal; Ovariectomy; Rats; Rats, Sprague-Dawley | 2019 |
High-dose diosgenin reduces bone loss in ovariectomized rats via attenuation of the RANKL/OPG ratio.
Topics: Animals; Body Weight; Bone Density; Bone Density Conservation Agents; Diosgenin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Estradiol; Estrogen Replacement Therapy; Female; Gene Expression Regulation; Humans; Organ Size; Osteoporosis, Postmenopausal; Osteoprotegerin; Ovariectomy; RANK Ligand; Rats; Rats, Wistar; Tibia; Uterus | 2014 |
Dioscin reduces ovariectomy-induced bone loss by enhancing osteoblastogenesis and inhibiting osteoclastogenesis.
Topics: Animals; Bone and Bones; Cell Differentiation; Cell Line; Cell Proliferation; Dioscorea; Diosgenin; Female; Humans; Mice, Inbred C57BL; Osteoblasts; Osteoclasts; Osteogenesis; Osteoporosis, Postmenopausal; Ovariectomy; Rats, Sprague-Dawley; Signal Transduction | 2016 |